Anti-CD38 monoclonal antibodies, including daratumumab and isatuximab, have been successful in treating refractory PRCA following allogeneic hematopoietic stem cell transplantation (aHSCT) with major ABO incompatibility [34–38]. This evidence concerns the gene CD38 and pure red-cell aplasia.